"10.1371_journal.pone.0146401","plos one","2016-01-13T00:00:00Z","Carl T Gustafson; Felix Boakye-Agyeman; Cassandra L Brinkman; Joel M Reid; Robin Patel; Zeljko Bajzer; Mahrokh Dadsetan; Michael J Yaszemski","Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate School, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55902, United States of America; Pharmacometrics Center, Duke Clinical Research Institute (DCRI), Durham, North Carolina 27705, United States of America; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic Infectious Disease Research Laboratory, Mayo Clinic, Rochester, Minnesota 55902, United States of America; Division of Biomathematics, Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55902, United States of America; Division of Biomathematics, Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55902, United States of America; Division of Orthopaedic Research, Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55902, United States of America","Conceived and designed the experiments: CTG FBA CLB JMR ZB MD MJY. Performed the experiments: CTG FBA CLB. Analyzed the data: CTG CLB ZB MD. Contributed reagents/materials/analysis tools: JMR RP ZB MJY. Wrote the paper: CTG FBA CLB JMR RP ZB MJY.","The authors of this manuscript report the following competing interests: patent for \"Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery.\" Inventors: Mahrokh Dadsetan, Michael Yaszemski, Lichun Lu. Filing Date: March 23, 2006. Patent number: US 8343527 B2. This competing interest affects co-authors MJY and MD. It does not alter the authorsâ€™ adherence to PLOS ONE policies on sharing data and materials.","2016","01","Carl T Gustafson","CTG",8,TRUE,7,3,4,7,TRUE,TRUE,FALSE,0,NA,FALSE
